• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
 
Trade NameBIOMERIEUX THXID BRAF ASSAY KIT
Classification Namesomatic gene mutation detection system
ApplicantBIOMERIEUX, INC.
PMA NumberP120014
Date Received07/31/2012
Decision Date05/29/2013
Product Code
OWD[ Registered Establishments with OWD ]
Docket Number 13M-0709
Notice Date 06/14/2013
Advisory Committee Immunology
Clinical Trials NCT01153763
NCT01227889
NCT01245062
NCT01266967
Expedited Review Granted? No
Combination Product Yes
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the thxid braf kit for use on the abi 7500 fast dx real-time pcr instrument. This device is indicated for: the thxid braf kit is an in vitro diagnostic device intended for the qualitative detection of the braf v600e and v600k mutations in dna samples extracted from formalin-fixed paraffinembedded (ffpe) human melanoma tissue. The thxid braf kit is a real-time pcr test on the abi 7500 fast dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry the braf v600e mutation for treatment with dabrafenib [tafinlar®] and as an aid in selecting melanoma patients whose tumors carry the braf v600e or v600k mutation for treatment with trametinib [mekinist].
Approval Order Approval Order
-
-